Aptamers Targeting Immune Checkpoints for Tumor Immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Tumor immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4, has transformed cancer treatment.
• Challenges with current ICIs include treatment resistance, immune-related adverse effects, and high costs, necessitating novel therapeutic strategies.

Purpose of the Study:

• To provide a comprehensive analysis of aptamer-based strategies for targeting immune checkpoints (PD-1/PD-L1 and CTLA-4) in cancer immunotherapy.
• To explore recent advances in aptamer design and strategies for enhancing their therapeutic potential.

Main Methods:

• Review of recent advances in aptamer design, including bispecific and multifunctional aptamers.
• Discussion of strategies for enhancing aptamer stability, bioavailability, and tumor penetration (chemical modifications, nanoparticle conjugation).
• Analysis of preclinical and early clinical studies on aptamer efficacy in blocking immune checkpoints and restoring T-cell activity.

Main Results:

• Aptamers demonstrate high specificity and affinity for target molecules, serving as promising alternatives to antibody-based therapies.
• Advanced aptamer designs (bispecific, multifunctional) show potential in overcoming immune resistance.
• Chemical modifications and nanoparticle conjugation can improve aptamer pharmacokinetics and tumor targeting.

Conclusions:

• Aptamers can effectively block immune checkpoint pathways, restore T-cell activity, and synergize with other immunotherapies for superior anti-tumor responses.
• Aptamer-based cancer immunotherapy holds significant promise for developing more effective and personalized treatment strategies.
• Further research and clinical studies are needed to fully realize the potential of aptamers in cancer treatment.